FDA panel pans PTC’s post hoc pitch, shredding DMD dream by Nick Paul Taylor Friday, September 29, 2017 A panel of experts convened by the FDA has overwhelmingly knocked back PTC Therapeutics’ filing for approval of ataluren.
PTC notches up failures in CF with ataluren, dumps program by Ben Adams Thursday, March 2, 2017 PTC Therapeutics is ending attempts to get its Duchenne drug ataluren onto the market in this disease setting after a key phase 3 trial flopped.
